Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation

Journal of Nephrology

Volumn 23, Issue 1, 2010, Pages 77-84

  Chitalia, Nihil ^a   Raja, Rickey Bipin ^a   Bhandara, Tharindu ^a   Agrawal, Pradeep ^b   Kaski, Juan Carlos ^c   Jha, Vivek ^b   Banerjee, Debasish ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adiponectin; Cardiovascular risk; Chronic kidney disease; Kidney transplantation

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 77249117698     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-1301.
2. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2000;103:1057-1063.
3. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767-2770.
4. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004;315:264-271.
5. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89:765-769.
6. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88:3236-3240.
7. Fernandez-Real JM, Castro A, Vazquez G, et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care. 2004;27:739-745.
8. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care. 2004;27:547-552.
9. Weyer K, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
10. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769.
11. Engeli S, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52:942-947.
12. Chow W-S, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5 year prospective study. Hypertension. 2007;49:1455-1461.
13. Hansen T, Ahlström H, Söderberg S, et al. Visceral adipose tissue, adiponectin levels and insulin resistance are related to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly population. Atherosclerosis. 2009;205:163-167.
14. Broedl UC, Lebherz C, Lehrke M, et al. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One. 2009;4:e4733.
15. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563-8256.
16. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones. 2006;5:259-269.
17. Steinvinkel P, Marchlewska A, Pecoits-filho R, et al. Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int. 2004;65:274-281.
18. Zocalli C, Mallamachi F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with ESRD. J Am Soc Nephrol. 2002;13:134-141.
19. Guebre-Egziabher F, Bernhard J, Funahashi T, et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005;20:129-134.
20. Rao M, Li L, Tighiouart H, et al. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant. 2008;23:2619-2628.
21. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645-1656.
22. Becker B, Kronenberg F, Kielstein JT, et al; MMKD Study Group. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the Mild and Moderate Kidney Disease Study. J Am Soc Nephrol. 2005;16:1091-1098.
23. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int. 2008;74:649-654.
24. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599-2606.
25. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant. 2004;4:1662-1668.
26. Johnson DW, Armstrong K, Campbell SB, et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology. 2007;12:391-398.
27. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation. 2007;100:2473-2476.
28. Ayerden Ebinc F, Ebinc H, Derici U, et al. The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol. 2009;22:216-223.
29. Chudek J, Adamczak M, Karkoszka H, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003;35:2186-2189.
30. Shen YY, Charlesworth JA, Kelly JJ, et al. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant. 2007;22:171-178.
31. Koshimura J, Fujita H, Narita T, et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun. 2004;316:165-169.
32. Adamczak M, Szotowska M, Chudek J, et al. Plasma adiponectin concentration in patients after successful kidney transplantation: a single-center, observational study. Clin Nephrol. 2007;67:381-390.
33. Dervisoglu E, Eraldemir C, Kalender B, et al. Adipocytokines leptin and adiponectin, and measures of malnutrition-inflammation in chronic renal failure: is there a relationship? J Ren Nutr. 2008;18:332-337.
34. Tsao YT, Hsu YJ, Chu NF, et al. Association of plasma adiponectin and cardiovascular risk profiles in non diabetic uremic patients on peritoneal dialysis. J Nephrol. 2008;21:744-752.
35. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756-1762.
36. Fasshauer M, Klein J, Neumann S, et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002;290:1084-1089.